In April 2020 Sirona launched an antiviral program based on research done by the company in 2019.
Viruses are a leading cause of death globally. Therapies to treat most viral infections are limited and the emergence of new viruses can greatly endanger society, as is currently the case with the pandemic caused by COVID. There is a need to identify novel, effective and safe drugs to treat viral infections. Awareness of the value of this project and other antiviral projects ongoing globally has become apparent.
Following two months of extensive research, TFChem scientists determined that the proprietary platform technology can be applied to develop new antiviral compounds. Work on this program has begun with a goal to produce new therapies in three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. These categories are all Glycosides with a carbohydrate core and therefore suitable for application of the technology.
The goal is to develop novel multi-target antiviral compounds, affecting different steps of the viral life cycle. The company believes there is a high therapeutic potential for these Glycosides.
Stay tuned for updates in 2022!
For any additional information please contact Michelle Seltenrich at firstname.lastname@example.org.